Vaccine against ISA will be commercialized this week

Besides ISA, this new product also protects against salmon rickettsial syndrome (SRS), Infectious Pancreatic Necrosis (IPN) and Vibrio Ordalli. The vaccine has been proved in a controlled environment, showing an efficiency rate of over 80%.

One of the characteristics of this vaccine, is that was developed with a national strain of the virus. "This advance is the result of long years of work of Chilean and foreign researchers", said the general manager of FAV, Carlos Gonzalez.

Ten years ago, FAV developed a vaccine against SRS, a disease that has constituted one of the principal causes of mortality in the local industry.